Immunogenicity risk management for commercial advantage.


The landscape of biologic drug development is shifting. Patent restrictions on the first generation of biologics will end soon, and for follow-on pharmaceutical development the weight is now behind drugs with known or existing mechanisms of action, such as biosimilars [1]. As a consequence, biologics of the future will not stand out by being ‘first in class’ blockbusters, but as a result of offering additional desirable product characteristics.

DOI: 10.1016/j.drudis.2012.12.010

Cite this paper

@article{Schwabe2013ImmunogenicityRM, title={Immunogenicity risk management for commercial advantage.}, author={Nikolai F. Schwabe and Victoria H. Lawson}, journal={Drug discovery today}, year={2013}, volume={18 9-10}, pages={417-9} }